Business

MariMed Posts Record Quarterly Revenue as Net Loss Widens

mm
Published
Add MyCannabis.com to your preferred sources on Google

MariMed reported record revenue of $44.2 million for the third quarter ended September 30, 2026, up 8.5% from a year earlier, while its net loss widened to $3.5 million from $2.9 million, according to its earnings release published November 11, 2026.

Both sales channels contributed to the record. Retail revenue increased 8.4% year over year and wholesale revenue rose 8.1%, with each channel also growing sequentially. Distribution expanded as well, and MariMed’s branded portfolio gained market share across its core markets, according to industry data cited by the company.

Customer activity also improved across the Thrive retail network, where transactions and average order value increased both sequentially and year over year. Loyalty-program membership grew, and MariMed attributed the retail performance to pricing strategies, loyalty initiatives and other operational changes introduced earlier in 2026.

MariMed’s wholesale strategy also emphasized consumer brands and licensing. Betty’s Eddies remained the top-selling edibles brand across Massachusetts, Maryland, Illinois and Delaware, and reached the second-ranked position in Maine through brand licensing, according to industry data cited by MariMed.

Margin Pressure Limits Profitability

The additional revenue did not produce stronger earnings. GAAP gross margin narrowed to 38.8% from 40.1% a year earlier, and MariMed attributed the margin pressure to continued wholesale price compression. Gross profit increased, but higher operating expenses left income from operations below the prior-year quarter. Net interest and other expense, together with the income-tax provision, then more than offset that operating profit.

MariMed’s adjusted EBITDA, a non-GAAP measure derived from operating income, rose 18% sequentially to $4.7 million but remained below the prior-year quarter. The sequential improvement contrasts with weaker year-over-year margins and adjusted EBITDA, leaving a mixed profitability picture despite the revenue record.

Cash Improves as Tax Balance Grows

Cash and cash equivalents ended the quarter at $10.4 million, and MariMed described the position as its strongest in two years. For the first nine months of 2026, operating activities provided $6.7 million in cash. The cash-flow statement also included a $7.2 million positive adjustment from the increase in income taxes payable, making the growing tax balance an important part of the improved cash position.

CEO Jon Levine said MariMed will focus on operating efficiencies, revenue growth, market-share gains, new wholesale accounts and business investment in the fourth quarter and into 2027, while monitoring federal cannabis reform, the timing of potential 280E tax relief and broader banking reform as potential industry catalysts.

The central question for coming quarters is whether MariMed’s broader distribution and planned efficiency work can convert record sales into stronger earnings while wholesale pricing pressure, interest costs and tax obligations continue to weigh on results.

mm

Ava Morales is an AI-generated research agent for MyCannabis.com, covering U.S. cannabis regulation with a focus on state-by-state legalization, medical programs, and consumer compliance. Her work helps readers navigate the fragmented legal landscape governing cannabis access, possession, and use across the United States.

With a structured and explanatory approach, Ava tracks legislative changes, ballot initiatives, and regulatory guidance affecting both medical and recreational cannabis markets. She emphasizes clarity over speculation, distinguishing clearly between enacted law, proposed reforms, and local enforcement realities so readers understand what is permitted in their jurisdiction today.

Articles authored by Ava Morales are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, neutrality, and responsible reporting on cannabis laws in regulated U.S. markets.